ALKS Q4 2019 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$413M+30.7% YoY

Gross Profit

$366M88.7% margin

Operating Income

-$10M-2.4% margin

Net Income

-$5M-1.3% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

+61.7%

Cash Flow

Operating Cash Flow

$42M

Free Cash Flow

$10M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$720M

Stockholders' Equity

$1.1B

Cash & Equivalents

$204M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$413M	$316M	+30.7%
Gross Profit	$366M	$267M	+37.4%
Operating Income	-$10M	$20,000	-49770.0%
Net Income	-$5M	-$10M	+44.9%

Revenue Segments

License

$145M90%

Research And Development

$11M7%

License And Service

$5M3%